ImmunityBio (IBRX) EBITDA Margin (2014 - 2026)
ImmunityBio (IBRX) recorded EBITDA Margin of -111.81% in Q2 2026, up 143.27 percentage points from -255.08% a year earlier and up 36.16 percentage points from the prior quarter.
Powered by 
Analysis
ImmunityBio (IBRX) EBITDA Margin (2014 - 2026) Analysis & Trends
On a TTM basis, ImmunityBio's EBITDA Margin came in at -141.86% as of Jun 30, 2026, up 333.52 percentage points year-over-year; for FY2025, it was -212.29%, up 2002.89 percentage points from FY2024.
- Annual EBITDA Margin has increased for three straight years, with a five-year change of +34191.18 percentage points (FY2020 to FY2025).
- Across earlier years, EBITDA Margin came in at -2215.18% in FY2024 (+53048.17 pp), -55263.34% in FY2023 (+83502.49 pp), -138765.83% in FY2022 (-104928.36 pp) and -33837.47% in FY2021 (+566.00 pp).
- The Q2 2026 figure is the highest quarterly EBITDA Margin in data going back to Q1 2014.
- On a year-over-year basis, EBITDA Margin has increased for nine consecutive quarters, with an average year-over-year change of +48171.51 percentage points over the last eight quarters.
- Peak year-over-year performance for EBITDA Margin in the last five years was a gain of 626605.83 percentage points in Q1 2023, against a drop of 596377.70 percentage points in Q1 2022 at the low end.
- Per Business Quant, the preceding three quarters came in at -147.97% (Q1 2026), -158.86% (Q4 2025) and -161.19% (Q3 2025).
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 655.56 Bn | 574.09 Bn | 17.26 Bn | 35.95% |
| 2 | AbbVie | 470.94 Bn | 444.10 Bn | 12.70 Bn | 49.01% |
| 3 | Merck | 367.14 Bn | 321.57 Bn | 12.21 Bn | 6.02% |
| 4 | Novartis Ag | 280.33 Bn | 236.20 Bn | 11.24 Bn | - |
| 5 | Astrazeneca | 257.78 Bn | 231.34 Bn | 12.86 Bn | 33.11% |
| 6 | Amgen | 226.04 Bn | 181.44 Bn | 7.24 Bn | 46.01% |
| 7 | Gilead Sciences | 188.89 Bn | 163.01 Bn | 6.22 Bn | -124.26% |
| 8 | Pfizer | 163.75 Bn | 110.70 Bn | 10.94 Bn | 39.16% |
| 9 | Vertex Pharmaceuticals | 133.68 Bn | 105.69 Bn | 2.84 Bn | 39.10% |
| 10 | ImmunityBio | 8.97 Bn | 7.74 Bn | 50.94 Mn | -111.81% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -111.81% |
| Mar 31, 2026 | -147.97% |
| Dec 31, 2025 | -158.86% |
| Sep 30, 2025 | -161.19% |
| Jun 30, 2025 | -255.08% |
| Mar 31, 2025 | -366.89% |
| Dec 31, 2024 | -864.17% |
| Sep 30, 2024 | -1,241.37% |
| Jun 30, 2024 | -9,066.57% |
| Mar 31, 2024 | -226,602.50% |
| Dec 31, 2023 | -58,147.48% |
| Sep 30, 2023 | -92,135.37% |
| Jun 30, 2023 | -196,251.22% |
| Mar 31, 2023 | -29,694.17% |
| Dec 31, 2022 | -109,142.47% |
| Sep 30, 2022 | -73,138.98% |
| Jun 30, 2022 | -214,794.29% |
| Mar 31, 2022 | -656,300.00% |
| Dec 31, 2021 | -19,404.87% |
| Sep 30, 2021 | -113,862.12% |
API Access
ImmunityBio EBITDA Margin API
Pull this series into your own models, spreadsheets and apps with the Business Quant
Historical Metrics API. The request below matches the chart above — change the
frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.
https://data.businessquant.com/historic?slug=ebitda-margin&ticker=IBRX&period=max&api_key=YOUR_API_KEYimport requests
url = "https://data.businessquant.com/historic"
params = {"slug": "ebitda-margin", "ticker": "IBRX", "period": "max", "api_key": "YOUR_API_KEY"}
data = requests.get(url, params=params).json()const res = await fetch("https://data.businessquant.com/historic?slug=ebitda-margin&ticker=IBRX&period=max&api_key=YOUR_API_KEY");
const data = await res.json();